417 related articles for article (PubMed ID: 15589591)
1. Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer.
Micha JP; Goldstein BH; Mattison JA; Bader K; Graham C; Rettenmaier MA; Brown JV; Markman M
Gynecol Oncol; 2005 Jan; 96(1):132-5. PubMed ID: 15589591
[TBL] [Abstract][Full Text] [Related]
2. Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer.
Micha JP; Goldstein BH; Rettenmaier MA; Mattison J; Graham C; Birk CL; Brown JV
Gynecol Oncol; 2004 Sep; 94(3):719-24. PubMed ID: 15350364
[TBL] [Abstract][Full Text] [Related]
3. Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan.
Liu FS; Ho ES; Hung MJ; Hwang SF; Lu CH; Ke YM
Gynecol Oncol; 2004 Aug; 94(2):393-7. PubMed ID: 15297178
[TBL] [Abstract][Full Text] [Related]
4. Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.
Gordon AN; Teneriello M; Janicek MF; Hines J; Lim PC; Chen MD; Vaccarello L; Homesley HD; McMeekin S; Burkholder TL; Wang Y; Zhao L; Orlando M; Obasaju CK; Gill JF; Tai DF
Gynecol Oncol; 2011 Dec; 123(3):479-85. PubMed ID: 21978765
[TBL] [Abstract][Full Text] [Related]
5. Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Look KY; Bookman MA; Schol J; Herzog TJ; Rocereto T; Vinters J;
Gynecol Oncol; 2004 Jan; 92(1):93-100. PubMed ID: 14751144
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning.
Hensley ML; Correa DD; Thaler H; Wilton A; Venkatraman E; Sabbatini P; Chi DS; Dupont J; Spriggs D; Aghajanian C
Gynecol Oncol; 2006 Aug; 102(2):270-7. PubMed ID: 16490239
[TBL] [Abstract][Full Text] [Related]
8. Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study.
Mäenpää JU; Grénman SE; Jalkanen JT; Kuoppala TA; Leminen AO; Puistola US; Vuolo-Merilä PM; Yliskoski MH
Gynecol Oncol; 2006 Apr; 101(1):114-9. PubMed ID: 16266743
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study.
Steer CB; Chrystal K; Cheong KA; Galani E; Marx GM; Strickland AH; Yip D; Lofts F; Gallagher C; Thomas H; Harper PG
Gynecol Oncol; 2006 Nov; 103(2):439-45. PubMed ID: 16643993
[TBL] [Abstract][Full Text] [Related]
10. Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study.
Papadimitriou CA; Fountzilas G; Aravantinos G; Kalofonos C; Moulopoulos LA; Briassoulis E; Gika D; Dimopoulos MA;
Gynecol Oncol; 2004 Jan; 92(1):152-9. PubMed ID: 14751151
[TBL] [Abstract][Full Text] [Related]
11. A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).
Schallier D; Neyns B; Fontaine C; Steene JV; De Mey J; Meysman M; De Grève J
Lung Cancer; 2007 May; 56(2):247-54. PubMed ID: 17337086
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
Alva A; Daignault S; Smith DC; Hussain M
Invest New Drugs; 2014 Feb; 32(1):188-94. PubMed ID: 24318901
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8).
du Bois A; Belau A; Wagner U; Pfisterer J; Schmalfeldt B; Richter B; Staehle A; Jackisch C; Lueck HJ; Schroeder W; Burges A; Olbricht S; Elser G;
Gynecol Oncol; 2005 Feb; 96(2):444-51. PubMed ID: 15661234
[TBL] [Abstract][Full Text] [Related]
15. Effects of sequential paclitaxel-carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study.
Wang F; Du X; Li X; Liu N; Yu H; Sheng X
Medicine (Baltimore); 2016 Dec; 95(51):e5696. PubMed ID: 28002342
[TBL] [Abstract][Full Text] [Related]
16. Improved survival with single-agent paclitaxel consolidation/maintenance therapy in advanced ovarian carcinoma.
Micha JP; Goldstein BH; Graham C; Rettenmaier MA; Brown JV; Hu JC; Markman M
Oncology; 2006; 71(1-2):49-53. PubMed ID: 17377414
[TBL] [Abstract][Full Text] [Related]
17. Dose intense triplet chemotherapy with gemcitabine, carboplatin, paclitaxel with peripheral blood progenitor cell support for six cycles in advanced epithelial ovarian cancer.
Barlow C; Nystrom M; Oesterling C; Fennell D; Ismay J; Gallagher C
Br J Cancer; 2004 Apr; 90(7):1318-22. PubMed ID: 15054448
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer.
Murad AM
Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):26-32. PubMed ID: 14768402
[TBL] [Abstract][Full Text] [Related]
19. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
